Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Current Deferred Tax Assets: 2011-2012

  • Lineage Cell Therapeutics' Current Deferred Tax Assets was N/A to $712,981 in Q3 2012 from the same period last year, while for Sep 2012 it was $712,981, marking a year-over-year change of. This contributed to the annual value of $843,944 for FY2011, which is N/A change from last year.
  • According to the latest figures from Q3 2012, Lineage Cell Therapeutics' Current Deferred Tax Assets is $712,981, which was down 5.75% from $756,510 recorded in Q2 2012.
  • Over the past 5 years, Lineage Cell Therapeutics' Current Deferred Tax Assets peaked at $843,944 during Q4 2011, and registered a low of $712,981 during Q3 2012.
  • In the last 2 years, Lineage Cell Therapeutics' Current Deferred Tax Assets had a median value of $756,510 in 2012 and averaged $771,145.